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Background: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is a cancer stem cell marker, and its
expression correlates with prognosis in a number of malignancies. The aim of this study is to determine the
relationship of ALDH1A1 expression with clinicopathological parameters and prognosis in gastric cancer.
Methods: ALDH1A1 and matrix metallopeptidase 9 (MMP-9) was evaluated by immunohistochemistry in 216
gastric carcinoma samples. The association between expression of ALDH1A1 and MMP-9, clinicopathological
parameters, and prognosis of gastric cancer was examined.
Results: ALDH1A1 protein expression was significantly associated with depth invasion, lymph node metastasis and
stage of disease (all P < 0.05). Both univariate and multivariate analyses revealed that ALDH1A1 was an independent
prognostic factor for both overall survival (OS) and recurrence-free survival (RFS) (both P < 0.001). Furthermore,
ALDH1A1 overexpression was associated with poor prognosis in patients subgroups stratified by tumor size, depth
invasion and lymph node metastasis. Moreover, ALDH1A1 was significantly correlated with MMP-9 among 216
gastric cancer tissues (P < 0.001). Patients who had ALDH1A1 overexpression, in which tumor cells displayed high
invasiveness, had poor OS and shorter RFS.
Conclusion: ALDH1A1 plays an important role in tumor aggressiveness and prognosis, and may act as a promising
target for prognostic prediction.Background
Gastric cancer is one of the leading causes of cancer-
related death worldwide due to its frequency, poor
prognosis and limited treatment options [1]. Complete
resection of the tumor and adjacent lymph nodes is the
only effective curative treatment [2]. Unfortunately, after a
complete resection, the 5-year survival rate remains low
[3]. Several studies have shown that various genetic and
epigenetic alterations are involved in the course of carcino-
genesis and progression of gastric cancer [4-6]. However,
the molecular mechanism involved in the development of
gastric cancer remains unclear.
Aldehyde dehydrogenases (ALDHs) are a group of
proteins that share highly conserved sequences essential
for function. Each subunit contains a catalytic domain, a* Correspondence: wsluo58@126.com
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unless otherwise stated.cofactor binding domain, and a bridging domain. Each
subtype’s catalytic pocket has a specificity for a parti-
cular substrate [7]. The human ALDH superfamily cur-
rently consists of 19 known putatively functional genes
in 11 families and 4 subfamilies with distinct chromo-
somal locations [7-9]. The ALDH enzymes can be found
in the cytosol, nucleus, mitochrondria, and endoplasmic
reticulum. The function of ALDH is to modulate several
cell functions, including proliferation, differentiation,
and survival, as well as the cellular response to oxidative
stress. It has been reported that the ALDH enzymes that
are involved in normal stem cells as well as cancer stem
cells include the ALDH1 family, ALDH2*2, ALDH3A1,
ALDH4A1 and ALDH7A1 [7]. In particular, ALDH1 has
been used as a marker to identify and isolate normal and
cancer stem cells. It has been known that the ALDH1 sub-
family comprises of ALDH1A1, ALDH1A2 and ALDH1A3.
ALDH1A1 is a cytosolic enzyme responsible for oxi-
dizing a variety of intracellular aldehydes to carboxylic
acids [10]. It also plays an important role in the detoxi-
fication of peroxidic aldehydes produced by ultraviolethis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic correlation of ALDH1A1
expression in 216 gastric cancer
Characteristics No. of
patients
ALDH1A1 expression (%) P-value
Negative Positive
Gender
Male 140 64 (45.7%) 76 (54.3%)
Female 76 44 (57.9%) 32 (42.1%) 0.087
Age (years)
≤ 60 136 74 (54.4%) 62 (45.6%)
> 60 80 34 (42.5%) 46 (57.5%) 0.091
Size (cm)
≤ 5.0 139 76 (54.7%) 63 (45.3%)
> 5.0 77 32 (41.6%) 45 (58.4%) 0.065
Tumor site
Upper 86 36 (41.9%) 50 (58.1%)
Middle/Lower 130 72 (55.4%) 58 (44.6%) 0.052
Differentiation
Well/Moderate 96 41 (42.7%) 55 (57.3%)
Poor 120 67 (55.8%) 53 (44.2%) 0.055
Depth of invasion
T1/T2 81 58 (71.6%) 23 (28.4%)
T3/T4 135 50 (37.0%) 85 (63.0%) < 0.001
Lymph node metastasis
Negative 59 46 (78.0%) 13 (22.0%)
Positive 157 62 (39.5%) 95 (60.5%) < 0.001
Stages
I/II 71 52 (73.2%) 19 (26.8%)
III 145 56 (38.6%) 89 (61.4%) < 0.001
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dition, it exhibits high activity for oxidation of aldopho-
sphamide and has a role in the detoxification of some
commonly used anticancer drugs [11]. Recently, it has
been reported that ALDH1A1 has been related to ad-
verse prognosis in several human malignancies, including
breast cancer, lung cancer, ovarian cancer and esophageal
cancer [12-15]. However, the role of ALDH1A1 on the
prognosis of patients with gastric cancer remains unclear.
In the present study, we assessed the expression of
ALDH1A1 in gastric cancer tissues by immunohistochem-
istry. Correlation of ALDH1A1 with clinicopathological
parameters and survival of gastric cancer patients were
then analyzed. In addition, it has been reported that
MMP-9 plays an important role in gastric cancer recur-
rence and prognosis [16]. Therefore, we also investigated




The study was approved by the Institutional Review Board
and Human Ethics Committee of Affiliated Hospital of
Guilin Medical University. Written consent for using the
samples for research purposes was obtained from all
patients prior to surgery.
Gastric carcinoma tissues were obtained from gastrec-
tomy specimens of 216 patients from the department of
general surgery, the Affiliated Hospital of Guilin Medical
University (Guilin, China). All the operations were per-
formed between January 2005 and December 2008. The
eligibility criteria of the current study were as follows:
(1) a pathologic examination confirming the presence of
gastric cancer and experienced radical surgery, (2) com-
plete basic clinical data, (3) the absence of any prior treat-
ment for cancer, and (4) no serious complications or other
malignant disease. There were 140 males and 76 females
(mean age, 57.0 years; range, 22–82 years). Relevant
clinical pathologic features (Table 1) were all obtained
from the patients’ files. Tumor stage was classified accor-
ding to the 7th Union International Cancer Control
(UICC) TNM staging system [17].
Immunohistochemistry staining
A total of 216 gastric carcinoma samples were used in
the immunohistochemistry (IHC) analysis. According to
protocol [18] for IHC on paraffin-embedded tissue sec-
tions, paraffin-embedded blocks were sectioned at about
4 μm thickness. Slides were baked at 60°C for 2 h, depar-
affinized with xylene and rehydrated using an alcohol
gradient (100% alcohol, 95% alcohol, 80% alcohol, and
70% alcohol). The tissue slides were then treated with
3% hydrogen peroxide in methanol for 30 min to quench
endogenous peroxidase activity, and the antigens wereretrieved in 0.01 M sodium citrate buffer (pH 6.0) using
a microwave oven. After 30 min of preincubation in 10%
normal goat serum to prevent nonspecific staining, the
samples were incubated overnight using a primary
antibody, either anti-ALDH1A1 (Abcam, #ab52492, UK,
dilution 1:200) or anti-MMP-9 (Abcam, #ab38898, UK,
dilution 1:200), in a humidified container at 4°C. The
tissue slides were treated with a non-biotin horseradish-
peroxidase detection system according to the manufac-
turer’s instructions (Gene Tech). The IHC results were
evaluated by two independent investigators blinded to
the patients’ identity and clinical status. In discrepant
cases, a pathologist reviewed the cases, and a consensus
was reached.
ALDH1A1 and MMP-9 staining intensities were rated
on a scale of 0–3 according to the percentage of positive
tumor (0, < 5% positive cells; 1, 5-10%; 2, 11-50%; or 3, >
50%). The expression is very low for 0, low for 1, moderate
for 2 and high for 3 (Figure 1). ALDH1A1 and MMP-9
Figure 1 Gastric cancer tissue illustrating the range of intensities of ALDH1A1 immunostaining from 0 to 3. The lower panels represent
magnified pictures of boxed area in the corresponding upper panels. The scale bar represents 50 μm.
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positive for scores ≥ 2.
Follow-up
The follow-up duration was defined as the interval be-
tween the date of operation and the date of death or last
follow-up. The study was censored on 30 September
2013. The median follow-up period was 27.0 months
(range, 4–82 months) in 216 patients. All the patients
were followed up every 1–3 months in the first year and
every 3–6 months thereafter. Recurrence were confirmed
by tumor markers levels including CEA, AFP, CA199,
CA125 and CA724, B-type ultrasonic inspection every 3
moths, and computed tomography (CT) or magnetic res-
onance imaging (MRI) every 6 months after gastrectomy.
The main causes of death were gastric cancer recurrence.
Overall survival (OS) was calculated from the date of
surgery to the date of death or last follow-up. Recurrence-
free survival (RFS) was defined as from the date of surgery
until the date of relapse or from the period of resection to
the date of the last observation taken.
Statistical analysis
All statistical analyses were performed using the SPSS
software (version 16.0; Chicago, IL, USA). Interdepen-
dence between ALDH1A1 status and clinical data was
calculated using the chi-square test, and displayed in
cross-tables. Correlation of ALDH1A1 with MMP-9 was
calculated by Pearson χ2 test. Survival curves were
plotted using the Kaplan-Meier method and analyzed using
the log-rank test. All reported P values were two-sided
and P < 0.05 was considered statistically significant.
Results
The association of ALDH1A1 with clinicopathological
variables
To elucidate the biological significance of ALDH1A1 in
gastric cancer, we examined the immunohistochemicalexpression of ALDH1A1 in gastric cancer tissues (Figure 1).
ALDH1A1 staining mainly located in cytoplasm of tumor
cells. The positive rate of ALDH1A1 was 50.0% (108/216)
in gastric cancer samples.
According to the results of immunohistochemistry, we
correlated ALDH1A1 status in 216 gastric cancer speci-
mens with clinicopathologic parameters (Table 1). Our
analyses showed that the level of ALDH1A1 in gastric
cancer was significantly correlated with depth of inva-
sion (P < 0.001), lymph node metastasis (P < 0.001), and
stage of disease (P < 0.001), but was not associated with
gender, age, tumor size, tumor site and grade of differen-
tiation (P > 0.05) (Table 1). Notably, the correlation of
ALDH1A1 with prominent serosal invasion and lymph
node metastasis positivity suggested a potential role of
ALDH1A1 in increased invasion and metastasis of gas-
tric cancer.
Effect of tumor ALDH1A1 protein level on prognosis
To further determine the effect of ALDH1A1 overex-
pression on the OS and RFS, we first performed univari-
ate analysis of traditional clinicopathologic variables for
prognosis. The results of the univariate analysis are shown
in Table 2. Overexpression of ALDH1A1 (P < 0.001), lar-
ger tumor size (P < 0.001), prominent serosal invasion
(P < 0.001) and lymph node metastasis (P < 0.001) were
significantly associated with the poor OS rate of gastric
cancer patients. In addition, Kaplan-Meier analysis
demonstrated that ALDH1A1 overexpression (P < 0.001),
larger tumor size (P = 0.001), tumor site (P = 0.047),
prominent serosal invasion (P < 0.001) and lymph node
metastasis (P < 0.001) were negative prognostic factors for
RFS in gastric cancer patients (Table 2). Furthermore, to
evaluate the independent impact of ALDH1A1 over-
expression on OS and RFS, a multivariate Cox regression
model adjusted for tumor size, tumor site, depth of
invasion, lymph node metastasis and ALDH1A1 expres-
sion was performed. Our results showed that ALDH1A1
Table 2 Predictive variables for overall survival and recurrence-free survival of 216 patients with gastric cancer
Variables No. of patients OS rate (%) P-value RFS rate (%) P-value
3 y 5 y 3 y 5 y
Gender
Male 140 46.9 39.6 41.5 35.4
Female 76 54.0 43.1 0.308 44.4 41.2 0.381
Age (years)
≤ 60 136 49.8 43.9 45.3 42.2
> 60 80 48.9 36.1 0.338 38.1 30.6 0.391
Size (cm)
≤ 5.0 139 55.6 47.4 50.4 45.5
> 5.0 77 38.1 28.8 0.001 28.3 23.3 < 0.001
Tumor site
Upper 86 45.9 33.8 34.6 28.6
Middle/Lower 130 51.8 45.7 0.074 47.8 43.7 0.047
Differentiation
Well/Moderate 96 47.8 39.7 41.2 34.6
Poor 120 50.7 41.6 0.673 43.6 40.1 0.822
Depth of invasion
T1/T2 81 71.4 66.5 70.2 65.3
T3/T4 135 36.2 25.5 < 0.001 25.6 20.8 < 0.001
Lymph node metastasis
Negative 59 83.5 79.2 82.0 77.5
Positive 157 36.5 26.6 < 0.001 27.5 22.6 < 0.001
ALDH1A1 protein expression
Negative 108 69.3 57.1 60.5 54.8
Positive 108 28.7 23.9 < 0.001 23.7 19.2 < 0.001
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OS in gastric cancer patients (hazard ratio, 2.037; 95% CI,
1.407 - 2.950). In addition, positive ALDH1A1 expression
patients were almost 2.0 times more likely to suffer from
relapse than those with negative ALDH1A1 expression
(hazard ratio, 1.945; 95% CI, 1.346 - 2.812). Tumor size,
depth of invasion and lymph node metastasis all had
independent prognostic value in the multivariate analysis
(Table 3).
Survival analysis showed that OS and RFS were signifi-
cant different among 216 patients according to the ex-
pression of ALDH1A1 (P < 0.001, P < 0.001) (Figure 2A).
The postoperative median OS and RFS were 27.0 months
and 19.0 months, respectively. The postoperative median
OS times in ALDH1A1-positive (n = 108) and ALDH1A1-
negative (n = 108) gastric cancer patients subgroup were
12.0 months and 42.0 months, and the median of the RFS
times were 9.0 months and 39.0 months. In addition, the
OS and RFS rates at 5 years were 23.9% and 19.2% for
ALDH1A1-positive patients compared with 57.1% and54.8% for ALDH1A1-negative patients, respectively (both
P < 0.001; Table 2).
To further evaluate the prognostic value of ALDH1A1
in different subgroups, patients were stratified according to
tumor size (Figure 2B,C), depth of invasion (Figure 2D,E)
and lymph node metastasis (Figure 2F,G). The expres-
sion of ALDH1A1 maintained its prognostic value in
predicting shorter OS and RFS in all of these subgroups
for except OS in T1/T2 subgroup (P = 0.054). Therefore, it
appears that ALDH1A1 may serve as a powerful prognos-
tic factor for patients with gastric cancer in different risk
groups.ALDH1A1 overexpression predict poor prognosis
independent of tumor invasiveness
To better understand the clinical significance of ALDH1A1
on aggressiveness in gastric cancer, we investigated the
relationship of ALDH1A1 and MMP-9 protein expression
in gastric cancer.
Table 3 Cox multivariate analysis of contributory factors to prognosis among 216 gastric cancer patients
after gastrectomy
Variables β SE Hazard ratio (95% CI) P-valuea
OS
Tumor size 0.410 0.177 1.507 (1.065 ~ 2.133) 0.021
Depth of invasion 0.576 0.255 1.779 (1.079 ~ 2.931) 0.024
Lymph node metastasis 1.018 0.341 2.767 (1.417 ~ 5.403) 0.003
ALDH1A1 protein expression 0.712 0.189 2.037 (1.407 ~ 2.950) < 0.001
RFS
Tumor size 0.411 0.178 1.508 (1.064 ~ 2.138) 0.021
Tumor site 0.043 0.180 1.044 (0.733 ~ 1.486) 0.813
Depth of invasion 0.649 0.256 1.913 (1.158 ~ 3.162) 0.011
Lymph node metastasis 1.063 0.338 2.894 (1.491 ~ 5.619) 0.002
ALDH1A1 protein expression 0.665 0.188 1.945 (1.346 ~ 2.812) < 0.001
Abbreviations: ALDH1A1 aldehyde dehydrogenase 1 family member A1, CI confidence interval.
aCox proportional hazards regression model.
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in the more prominent serosal invasion group (T3/T4)
and more frequent lymph node involvement group (N1-3),
while there were only 28.4% and 22.0% in T1/T2 and N0
(P < 0.001 and P < 0.001, respectively) (Table 1). In addi-
tion, ALDH1A1 was significantly correlated with MMP-9
in 216 gastric carcinoma specimens. Of 108 patients with
low ALDH1A1 expression, 81 patients (75.0%) had low
MMP-9 expression, while 71 of 108 patients (65.7%) with
high ALDH1A1 expression also had high MMP-9 expres-
sion (P < 0.001) (Figure 3).
We further explored the influence of tumor invasive-
ness on the prognostic value of ALDH1A1 expression
in gastric cancer by using MMP-9 as an indicator for
the invasive potential of individual tumor cells. All the
patients were stratified into either a low invasiveness
subgroup (low MMP-9 expression; n = 118) or a high
invasiveness subgroup (high MMP-9 expression; n = 98)
according to the MMP-9 expression index. Kaplan-Meier
survival curves were then plotted to investigate the asso-
ciation between ALDH1A1 status and survival (Figure 4).
In the low invasiveness subgroup, ALDH1A1 over-
expression was associated with shorter OS (P < 0.001) and
RFS (P < 0.001) compared with the OS and RFS in
patients with low ALDH1A1 expression (Figure 4A). In
the high tumor invasiveness subgroup (Figure 4B),
patients with ALDH1A1 overexpression were prone to
death (P < 0.001) and relapse (P < 0.001). Furthermore,
the 5-year survival rate was significantly lower in the
low invasiveness subgroup with ALDH1A1 over-
expression (23.8%) than that in the high invasiveness
subgroup with low ALDH1A1 expression (53.0%; P =
0.002; data not shown). Therefore, the expression of
ALDH1A1 appears to be a strong postoperativeprognostic parameter for patients with gastric cancer
independent of tumor invasiveness.
Discussion
In the present study, the expression of ALDH1A1 was
investigated in 216 gastric carcinoma tissues by im-
munohistochemistry. We found that ALDH1A1 was
significantly associated with depth invasion, lymph node
metastasis and stage of disease. In addition, the Kaplan-
Meier survival analysis revealed that the survival times
(OS and RFS) of gastric cancer patients with high
ALDH1A1 expression were significantly shorter than
those with low ALDH1A1 expression. The prognostic
value of ALDH1A1 in different subgroups according to
tumor size, depth of invasion and lymph node metasta-
sis was also estimated, which appears that ALDH1A1
may serve as a powerful prognostic factor for patients
with gastric cancer in different risk groups. Further-
more, the multivariate Cox model analysis indicated
that ALDH1A1 status was an independent factor for
both prognosis indexes (OS and RFS) in gastric cancer.
This finding suggests that ALDH1A1 plays an im-
portant role in tumor prognosis, concludes ALDH1A1
could be a potential prognostic factor of gastric cancer.
Our results were consistent with previously reported
results. In several investigations, it has been shown
that the abnormal expression of ALDH1A1 in cancer
cells is associated with tumor progression. Wakamatsu
et al. [19] revealed that ALDH1 was overexpression
and had positively correlated with depth invasion and
TNM stage in gastric cancer, moreover, ALDH1 posi-
tivity was significantly higher in diffuse-type lymph node
metastasis than that in the primary tumor. Charafe-
Jauffret et al. [20] reported that the ALDH1A1-positive
Figure 2 Overall survival and recurrence-free survival are shown for patients with gastric cancer. All patients were stratified according to
tumor size, depth of invasion and lymph node metastasis. Kaplan-Meier survival estimates and log-rank tests were used to analyze the prognostic
significance of ALDH1A1 expression in all patients (A) and each subgroup (B-G).
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in vitro and tumor metastasis in mouse xenografts, more-
over, expression of ALDH1A1 was an independent pre-
dictive factor for early metastasis and decreased survival
in inflammatory breast cancer. Jiang et al. [14] showed
that the ALDH1A1-positive lung cancer cells could
generate tumors in vivo, furthermore, the expression of
ALDH1A1 was positively correlated with the stage andgrade of lung tumors and related to a poor prognosis for
the patients with early-stage lung cancer, which suggested
that ALDH1A1 could be a potential prognostic factor and
therapeutic target for treatment of the patients with lung
cancer. However, Dimou et al. [21] found the contradictory
results that the ALDH1A1-negative expression of lung cancer
patients had shorter survival compared with those with
ALDH1A1-positive expression, which indicated that
Figure 3 ALDH1A1 and MMP-9 levels correlated in 216 gastric cancer tissues. (A, B) IHC staining for ALDH1A1 and MMP-9 was performed
in tumors from 216 gastric cancer patients. Representative examples of ALDH1A1 and MMP-9 staining in serial sections from the same tumor
samples are shown in (A), and percentages of samples displaying low or high ALDH1A1 expression relative to MMP-9 level is shown in (B).
The scale bar represents 200 μm.
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outcome.
It has been known that degradation of extracellular
matrix (ECM) was a signal for the beginning of invasion
and metastasis, and MMPs are important molecules
involved in ECM degradation during invasion and
metastasis [22]. Chu et al. [16] reported that cancer MMP-
9 was significantly correlated with depth of invasion and
lymph node metastasis and MMP-9-positive gastric cancer
patients had worse outcomes than those with MMP-9-
negative tumors. Zhao et al. [23] found that MMP-9Figure 4 Overall survival and recurrence-free survival are
shown for patients with low tumor invasiveness (A) and high
tumor invasiveness (B). Kaplan-Meier survival estimates and
log-rank tests were used to analyze the association between ALDH1A1
expression and overall survival or recurrence-free survival in patients
with low invasiveness (low MMP-9; n = 118) or high invasiveness
(high MMP-9; n = 98).targeted RNA interference was able to successfully sup-
press MMP-9 expression and inhibit cell growth and inva-
sion of SGC7901 gastric cancer in vitro and in vivo. Our
results demonstrated that the expression of ALDH1A1
and MMP-9 was correlated with each other, indicating
higher invasive and metastasizing activity in ALDH1A1
overexpression cancer cells. In addition, ALDH1A1 was
highly expressed in depth of invasion, especially in T3 and
T4 carcinomas, which was consistent with previously
reported results [19]. As far as lymph node status was
concerned, the patients with lymph node metastasis
tend to show elevated ALDH1A1 expression. Collectively,
ALDH1A1 status in gastric cancer promoting tumor
aggressiveness suggests that ALDH1A1 could be a feasible
target in cancer therapy.
Conclusions
In this study, we demonstrated that ALDH1A1 may play
an important role in tumor invasion, metastasis and
prognosis, and could work as a promising target for
prognostic prediction in gastric cancer. Determination of
ALDH1A1 expression may help to identify high-risk
gastric cancer patients and thus aid the selection of
appropriate therapies. Further investigation is necessary
to clarify the role of ALDH1A1 in the development of
gastric cancer.
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